Podcast: SUNY's Kirsten Gruis MD talks diaphragm pacing, an emerging treatment strategy that aims to help people breathe better and live longer.

An upcoming US trial aims to determine whether the diaphragm pacer helps people with ALS breathe better and live longer.

GSK's ozanezumab aims to keep people with ALS moving by helping muscles and motor nerves stay connected.

Twenty years ago today, scientists discovered the first gene linked to ALS, SOD1. Explore this interactive timeline to learn more about SOD1 and its impact on the ALS field.

An upcoming clinical trial asks whether the FDA-approved heart medicine mexiletine might slow ALS by reducing hyperexcitability, a potential early step in the disease.

Biogen Idec's Doug Kerr MD PhD talks dexpramipexole - the lessons learned and the development of future ALS medicines going forward.

Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.

New stem cell technologies, potential treatment strategies and emerging models of ALS top the list of advances unveiled at SfN12.